Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, Chinese University of Hong Kong, Shenzhen, 518172, China.
Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.
J Am Chem Soc. 2022 May 4;144(17):7568-7572. doi: 10.1021/jacs.2c00853. Epub 2022 Apr 18.
The COVID-19 pandemic has been a public health emergency with continuously evolving deadly variants around the globe. Among many preventive and therapeutic strategies, the design of covalent inhibitors targeting the main protease (M) of SARS-CoV-2 that causes COVID-19 has been one of the hotly pursued areas. Currently, about 30% of marketed drugs that target enzymes are covalent inhibitors. Such inhibitors have been shown in recent years to have many advantages that counteract past reservation of their potential off-target activities, which can be minimized by modulation of the electrophilic warhead and simultaneous optimization of nearby noncovalent interactions. This process can be greatly accelerated by exploration of binding affinities using computational models, which are not well-established yet due to the requirement of capturing the chemical nature of covalent bond formation. Here, we present a robust computational method for effective prediction of absolute binding free energies (ABFEs) of covalent inhibitors. This is done by integrating the protein dipoles Langevin dipoles method (in the PDLD/S-LRA/β version) with quantum mechanical calculations of the energetics of the reaction of the warhead and its amino acid target, in water. This approach evaluates the combined effects of the covalent and noncovalent contributions. The applicability of the method is illustrated by predicting the ABFEs of covalent inhibitors of SARS-CoV-2 M and the 20S proteasome. Our results are found to be reliable in predicting ABFEs for cases where the warheads are significantly different. This computational protocol might be a powerful tool for designing effective covalent inhibitors especially for SARS-CoV-2 M and for targeted protein degradation.
新冠疫情是一场公共卫生紧急事件,在全球范围内不断出现致命的变异病毒。在众多预防和治疗策略中,设计针对导致 COVID-19 的 SARS-CoV-2 主要蛋白酶 (M) 的共价抑制剂一直是热门研究领域之一。目前,约 30%的靶向酶的上市药物是共价抑制剂。近年来,这些抑制剂具有许多优势,可以抵消过去对其潜在非靶标活性的保留意见,通过调节亲电弹头并同时优化附近的非共价相互作用,可以将其最小化。通过使用计算模型探索结合亲和力,可以大大加速这一过程,但由于需要捕捉共价键形成的化学性质,该模型尚未得到很好的确立。在这里,我们提出了一种用于有效预测共价抑制剂绝对结合自由能 (ABFE) 的稳健计算方法。这是通过将蛋白质偶极 Langevin 偶极子方法(在 PDLD/S-LRA/β 版本中)与弹头及其氨基酸靶标在水中的反应的量子力学计算相结合来实现的。该方法评估了共价和非共价贡献的综合效应。该方法的适用性通过预测 SARS-CoV-2 M 和 20S 蛋白酶体的共价抑制剂的 ABFE 来说明。我们的结果在预测弹头明显不同的情况下预测 ABFE 是可靠的。该计算方案可能是设计有效共价抑制剂的有力工具,特别是针对 SARS-CoV-2 M 和靶向蛋白降解。